{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-130855","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.878992+00:00","generated_at":"2026-05-29T00:05:14.941208+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fennec announces NICE recommends PEDMARQSI for cisplatin-induced hearing loss in children in England and Wales","bullets":["NICE issued positive final draft guidance recommending PEDMARQSI for prevention of cisplatin-induced hearing loss in patients aged 1 month-17 years with localized solid tumors.","First and only approved therapy in EU/U.K. for cisplatin-induced ototoxicity prevention; Phase 3 trials showed ~50% reduction in hearing loss.","Fennec's partner Norgine will commercialize in Europe; Fennec received ~$43M upfront and is eligible for up to ~$230M milestones plus double-digit tiered royalties.","Until now, no preventative pharmacological intervention was available despite significant lifelong impact of hearing loss on pediatric cancer patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-130855","json":"https://secwatch.observer/filing/0001104659-24-130855.json","markdown":"https://secwatch.observer/filing/0001104659-24-130855.md","text":"https://secwatch.observer/filing/0001104659-24-130855.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924130855/0001104659-24-130855-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924130855/tm2431725d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T00:05:14.941208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}